<DOC>
	<DOCNO>NCT01621880</DOCNO>
	<brief_summary>Bevacizumab may better effect brain necrosis cause radiotherapy.This randomized trial aim investigate whether bevacizumab may alleviate radiation-induced brain necrosis patient nasopharyngeal carcinoma . The effect compare outcome patient receive steroid therapy .</brief_summary>
	<brief_title>Effect Bevacizumab Radiation-induced Brain Necrosis Patients With Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Radiation-induced brain necrosis severe complication radiotherapy patient Nasopharyngeal carcinoma . Current neuroprotective therapy show limited benefit ameliorate complication radiotherapy . This study randomize , single blind clinical study . The primary aim study determine whether bevacizumab alleviate radiation-induced brain necrosis patient nasopharyngeal carcinoma , compare treat effect bevacizumab steroid .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients must receive radiotherapy histologically confirm nasopharyngeal carcinoma . Prior irradiation &gt; /= 6 month prior study entry . Radiographic evidence support diagnosis radiationinduced brain necrosis without tumor recurrence . Age &gt; /= 18 year . Because dose adverse event data currently available use bevacizumab patient &lt; 18years old . No prior bevacizumab therapy . No evidence high intracranial pressure suggest brain hernia need surgery . Fertile woman willing take contraception trial . Routine laboratory study bilirubin &lt; /=2 * upper limit normal ( ULN ) , aspartate aminotransferase ( AST SGOT ) &lt; 2 * ULN , creatinine &lt; 1.5 * ULN , redcell count &gt; /= 4,000 per cubic millimeter ; whitecell count &gt; /=1500 per cubic millimeter , platelet &gt; /= 75,000 per cubic millimeter ; Hb &gt; /=9.0 . PT , APTT , INR normal range . If history seizure , patient anticonvulsant therapy . However , preference enzymenoninducing anticonvulsant . Ability understand willingness sign write informed consent document . The patient active bleed pathological condition carry high risk bleeding ; evidence serious nonhealing wound , ulcer bone fracture . Patients follow exclude : 1 ) evidence metastatic disease ; 2 ) evidence tumor invasion major vessel ( e.g . carotid ) ; 3 ) history bleed related tumor radiotherapy completion radiation . Evidence active central nervous system hemorrhage . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day prior study enrollment . inadequately control hypertension ( systolic blood pressure ( SBP ) &gt; 140 mmHg and/or diastolic blood pressure ( DBP ) &gt; 90 mmHg despite antihypertensive medication ) Severe complication : 1 ) History large vessel cerebrovascular accident ( CVA ) within 6 month ; 2 ) Myocardial infarction unstable angina within 6 month ; 3 ) New York heart association grade II great congestive heart failure ; 4 ) Serious inadequately control cardiac arrhythmia ; 5 ) Significant vascular disease ( e.g . aortic aneurysm , history aortic dissection ) ; 6 ) Clinically significant peripheral vascular disease ; 7 ) severe infection . Evidence bleed diathesis coagulopathy . Patients receive steroid therapy radiationinduced brain necrosis study . History anaphylactic response bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>radiation-induced brain necrosis</keyword>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Methylprednisolone</keyword>
</DOC>